Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Agonists and antagonists of the GIP receptor influence body weight ... At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood sugar levels. In addition, GLP ...

At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood ... GLP-1 reduces the feeling of hunger via specific satiety centers in the brain. GIP also appears to ...

Agonists and antagonists of the GIP receptor influence body weight ... At the same time, GLP-1 inhibits the release of glucagon, a hormone that increases blood sugar levels. In addition, GLP ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...